According to a new study of researchers from the University of Umea in Sweden, the combination from vaccines against him Covid-19 it is effective. According to data from analyzed from more than 700 thousand people.
People who have received a first dose of the Covid-19 vaccine from Oxford / AstraZeneca and a second mRNA had a lower risk of infection compared to those who received both doses of the first preparation. In messenger RNA (mRNA) vaccines, such as that of Pfizer-BioNTech and Moderna, ribonucleic acid is used to achieve the development of an immune response.
The professor of geriatric medicine at the aforementioned university, Peter Nordström, who has carried out the research, has stressed that any vaccine passed is better than none.
“However, our study shows a greater risk reduction for people who received an mRNA vaccine after receiving a first dose of a vaccine vector-based, compared to people who received the vector-based vaccine for both doses, “added the specialist, whose study has been published in the journal Lancet Regional Health.
When stopping the use of the vaccine vector-based Oxford-AstraZeneca for people under 65 years of age, all people who had already received their first dose of this preparation were recommended one of mRNA as the second dose.
Conclusions of the new study
During an average follow-up period of more than two months after the second dose, the study showed a 67% lower risk of infection for the combination of Oxford-AstraZeneca and Pfizer-BioNTech, and 79% less risk for Oxford / AstraZeneca and Moderna, both compared to unvaccinated individuals.
For people who received two doses of the Oxford-AstraZeneca vaccine, the risk reduction was 50%.
These risk estimates were observed after accounting for differences with respect to vaccination date, age of participants, socioeconomic status, and other risk factors for Covid-19.
The investigators have pointed out that the efficacy estimates were applied in relation to the infection by the Delta variant, which dominated the cases during the follow-up period.
Previous research has shown that combined vaccination programs elicit a robust immune response, but it is not clear to what extent these schedules can reduce the risk of clinical infection, according to the analysis.
The Umea study, which analyzed the cases of 700,000 people, is based on data from national registries from the Swedish Public Health Agency, the Swedish National Board of Health and Welfare and Statistics.
The results of the study may have implications for vaccination strategies in different countries, according to experts.
With information from EFE
Covid-19: Mexico will package Sputnik V vaccine from November
Third wave Covid-19: SSa reports 284 thousand 477 confirmed deaths
41 hospitals in Jalisco will vaccinate adolescents with vulnerable conditions against Covid-19